Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab
Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® In Advanced Renal Cell Carcinoma
SAGA Metals Announces Closing of Fully Subscribed Non-Brokered Private Placement and Provides Corporate Update
Locksley Announces Major Advancement at Mojave as Structural Mapping Expands Scale of Antimony Target with a 400% Increase in Target Strike Length
